Mr. Robert Andersson

Chief Executive Officer & President | Oriola

Mr. Robert Andersson is President & CEO of Oriola Corporation, the Finnish publicly listed company with a strong position in the Swedish and Finnish health and wellbeing market. He joined the company in February 2018. Prior to joining Oriola, Andersson held several senior roles in Telia Company including Senior Vice President and Head of Corporate Holdings, Executive Vice President and Head of Region Europe, and President and CEO of TeliaSonera, Finland. He was a member of Telia Company’s Group Management since 2012. Prior to Telia Company, Andersson held several international managerial and executive positions within Nokia, including serving on Nokia’s Group Executive Board 2005-2009 as Executive Vice President Customer and Market Operations and Executive Vice President Devices Finance, Strategy and Sourcing.

Mr. Francesco Balestrieri

Head of Europe - Ad Interim CEO | Sandoz International GmbH

Francesco Balestrieri is ad interim CEO of Sandoz, effective April 1, 2019.

Mr. Balestrieri joined Novartis in 1993 and has spent the past eight years in leadership roles at Sandoz. He has been Head of Europe since 2018, before he got appointed CEO ad interim for Sandoz. Prior he led the region Central and Eastern Europe, the Middle East and Africa from 2015 to 2018. He also worked as Region Head of Central and Eastern Europe from 2013 to 2015, and Region Head of Asia-Pacific from 2011 to 2013.
Before that, Mr. Balestrieri held roles including President of the Americas at Ciba Vision, and General Manager of Germany, Austria and Switzerland at Ciba Vision.

Mr. Balestrieri received a Master of Business Administration from the University of Venice in Italy. He is a Board member of Sandoz Italy, Sandoz Spain and Sandoz Nordics.
Additionally, he serves on the supervisory board of Lek, a Sandoz company, and on the executive committee of Medicines for Europe.

Mr. Richard Bergström

VP Life Sciences | Guardtime

Richard Bergstrom is a pharmacist by training. He received his MScPharm degree from the University of Uppsala, Sweden in 1988. Until 1992 he worked at the Medical Products Agency as Deputy Head of Registration. He moved to Switzerland where he worked for nine years in regulatory affairs at Roche and Novartis. Before moving back to Sweden, he was Director of EU Regulatory Strategy at Roche Basel. Between 2002 and 2011 he was Director-General of LIF, the Swedish Pharmaceutical Industry Association. While at LIF he was also an advisor to the World Health Organisation on Good Governance in Medicine, and a member of the Board of the Karolinska Institute, appointed by the Swedish government.

Between April 2011 and December 2016 he was the Director General of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and in that capacity also Board member of the Innovative Medicines Initiative (IMI) and the European Medicines Verification Organisation (EMVO).

He later led the pharma sector at SICPA, a Swiss privately held company that provides security solutions for governments until becoming VP Life Sciences for Guardtime.

Mr. Dirk Bockelmann

Global Commercial Director | BD Rowa

Dirk Bockelmann is the Global Commercial Director at BD Rowa. He joined the company in 2013, boasting 18-year experience in the IT sector.

Previously to BD Rowa, Dirk held the position of Director Field Operations and Marketing Manager at Wincor Nixdorf. From 2008 to 2013, he worked for NCR Corporation as EMEA Sales Director and Business Development Manager.

Ms. Junpei Cheng

Deputy Director | China Association of Pharmaceutical Commerce and Venture Partner of Sinopharm Capital

Ms. Junpei Cheng obtained her Bachelor of Economics from the Shanghai University of International Trade and Economics in China in 1984. In 1987 she received stipend from the United Nations and gained her MBA degree at the University of Neijenrode in the Netherlands in 1989.
Ms. Cheng joined the German retail giant ASKO Group (now Metro AG) in 1990 as Controller in ASKO’s subsidiary Comco Service and Production Co. KG where she was trained to become a supply chain professional and contributed the highest delivery performance (99.99% on-time delivery) in the industry.In 1995 Ms. Cheng was expatriated to China as General Manager by the Swiss family company Edward Keller Group (nowadays DKSH, DiethelmKellerSiberHegner) to set up Edward Keller (Shanghai) Ltd., which was one of the first few foreign distribution companies in China and also a pioneer in pharmaceutical distribution as a foreign company.

Ms. Cheng joined Sinopharm in 2001 and supported the successful establishment of Sinopharm Group Co. Ltd. (HK 1099) in 2003, where she held the position of Vice General Manager in charge of strategy and logistics. After a couple of years as independent consultant Ms. Cheng rejoined Sinopharm in 2011 with the mission to build up the supply chain competence for Sinopharm Group. Within less than four years, she successfully established Sinopharm Logistics as the leading brand for 3PL logistics and supply chain service providers in the Chinese health care sector. During her appointment Ms Cheng designed and launched the industry pioneering cloud platform named SAVE (abbreviated from Safety, Accessibility, Visibility and Efficiency) with whole supply chain visibility and real-time optimization. As of January 2015 Ms. Cheng was appointed General Manager of Sinopharm Group Distribution Co. Ltd., the biggest single distribution company in the market to incubate new service models for the Group.

As of 1 June 2016, Ms Cheng started her new venture with the leading health care eCommerce enterprise 111.com.cn (Nasdaq YI) as Vice President and CEO for B2B business.
Ms Cheng is meanwhile Deputy Director of China Association of Pharmaceutical Commerce and Venture Partner of Sinopharm Capital.

Ms. Monika Derecque-Pois

Director General | European Healthcare Distribution Association (GIRP)

Monika Derecque-Pois was born in Graz/Austria and holds a master’s degree in Economics from the University of Economics in Vienna, where she specialised in International Trade and Marketing.
Ms. Monika Derecque-Pois is the Director General of GIRP, the European Healthcare Distribution Association, which brings together over 750 pharmaceutical full-line wholesaling companies and their national associations from 35 countries. Monika was appointed to her current position in 2001, having previously served as European affairs consultant for GIRP. She has over 20 years of experience in European public affairs.
Prior to her engagement with GIRP, she served as a director in a European affairs consultancy company and she also held a six-year post as Marketing and Client Support Manager at IMS Health Austria.

Mr. Leonardo Ferrandino

President and Group CEO | Dr.Max

Leonardo was appointed as President and Group CEO in September 2016; since then he has been responsible for the management of the entire Dr.Max Group. His role and direct responsibility is to further strengthen and expand Dr. Max operations inside and outside of the traditional markets of Czech Republic, Slovakia and Poland.

Leonardo started his working career at Ernst & Young in 1995, gaining significant financial experiences and holding positions of increasing responsibility until 2003. Then he joined Admenta Italia (Celesio Group) in January 2004 where had several roles in the Finance and Business areas. From 2012 he served also as member of Celesio’s Group Executive Committee and in 2014 in addition to his business responsibility for Italy and Slovenia he gained the lead of "Group Sales" and "Group Marketing" and the Executive responsibility for the development of European Pharmacy Network (EPN) of Celesio.

Dr.Max is a leading pharmacy chain in Europe. Currently operating in 8 Countries with more than 2.100 pharmacies and 16.000 employees; it is dedicated to improving the level of health care available by guaranteeing access to a broad assortment of medicines and pharmacy services. Dr.Max Group is fully owned by Penta Investments, an investment group operating Europe, that has been involved in the healthcare industry since 2002, investing in health insurance, hospitals, outpatient clinics, pharmacies and laboratories. Dr. Max streams of business include pharmacies, wholesale and pharma marketing and sales divisions.

Dr. Jürg Gasser

Head of Projects -Specialty Care | Galenicare Management AG

After obtaining his PhD in Biochemistry and Molecular Biology, Dr. Gasser served in Inmuno AG for 3 years as the General Manager. He later held the positions of General Manager and Chairman of the Board at Baxter Healthcare. In 2004, he was appointed CEO and Board Member of MediCentrix. After some years, Dr. Gasser joined MediService as the CEO. He is currently the Head of Projects, Specialty Care, at GaleniCare Management.

Mr. Bernd Grabner


Mr Bernd Grabner is Member of the board of Jacoby GM Pharma and Vice-President of PHAGO, the Austrian Association of Pharmaceutical full-line Wholesalers. He has also been Member of the GIRP Board since June 2015.

Mr Grabner started his studies in law and business economics in Linz in 1993. While still studying, he worked in the family-owned wholesaling company, where he was in charge of a wide range of operational tasks.

Mr Grabner became member of the board of GM Pharma in 2003. Since the merger with Jacoby Pharmazeutika in July 2013, he has been member of the board of Jacoby GM Pharma and therein responsible for the division supplier relations, key account management for dispensing doctors and new business activities.

Mr. Kai Kaasalainen

Chief Executive Officer | Tamro Corporation

Kai Kaasalainen is a Finnish business leader and Managing Director of the pharmaceutical wholesaler and service company Tamro Corporation in Finland.

He has been working more than 10 years in Tamro and before that more than 20 years in high tech companies in the Retail sector.
He is also well known as an influencer, public speaker, blogger and he was rewarded the Finnish “Thought leader of the year 2018” title.

Mr. Kevin Kettler

Chairman of the Management Board | McKesson Europe AG

Kevin Kettler is Chairman of the Management Board of McKesson Europe AG. In this role, he is responsible for leading the company’s businesses in 13 European countries.
Previously, Kettler was President of McKesson Global Procurement and Sourcing in London. There, he led McKesson’s global pharmaceutical procurement program as well as international teams responsible for growing McKesson’s private label generics portfolio, NorthStar, and the globally-sourced medical surgical portfolio.

Prior to this role, Kevin Kettler was Senior Vice President of Marketing for McKesson U.S. Pharmaceutical (US Pharma). During his time in this role, he had accountability for market strategy, product development and customer programs for all customer market segments of the US Pharma business; he also had direct responsibility for four standalone businesses: AccessHealth, McKesson Patient Relationship Solutions, Macro Helix and Supplylogix. For Supplylogix and Macro Helix, he led the acquisition and post-acquisition growth of the businesses.
Kevin Kettler previously held various roles in McKesson’s Corporate Strategy and Business Development group including Senior Vice President of Corporate Strategy and Business Development supporting US Pharma. He was responsible for developing the overall strategic and market direction for the US Pharma business. On the business development side, he evaluated, negotiated and assisted in the integration of acquisitions.

Prior to his role in Corporate Strategy and Business Development, Kevin Kettler was a consultant to McKesson leading the integrations of acquired businesses into McKesson systems and processes.
Before McKesson, Kettler held various product marketing, product management and consulting roles in early stage start-ups. Prior to this, he was a materials supervisor for a medical device company now owned by Siemens, and he began his career as a project engineer for Amoco Oil.

Kevin Kettler, born in Michigan, USA, holds an MBA from the University of North Carolina, Chapel Hill and a BS in Mechanical Engineering from the University of Notre Dame.

Mr. Doug Long

Vice President Industry Relations | IQVIA

Doug Long is Vice President of Industry Relations at IQVIA, the world’s largest pharmaceutical information company. Doug has been with IMS since 1989. His fundamental task is to help secure data for all existing and new databases supported by IQVIA, manage supplier, manufacturer & association relationships, and develop information for data partners. As direct consequence of his involvement in these areas, Doug has considerable experience with, a unique perspective on, the changing U.S. and global healthcare marketplace and pharmaceutical distribution.

Although well versed in the global pharmaceutical market, the heart of Doug’s Industry year review is that of trends and forecasts in the US. Doug is current on topics such as mergers and acquisitions, tiered co-pay, generics, biologics, PBM’s and other emerging channels, and is also an expert on the complex issue of patient privacy.

Doug was honored with the 2004 HDMA Nexus Award for lifetime achievement and received IMS’s prestigious Summit award in 2003.

Prior to IMS HEALTH, Doug was at Nielsen Market Research for sixteen years in various sales and marketing capacities. A native of Illinois, Doug received a BA degree from the DePaw University in Greencastle, Indiana, and an MBA in Management from Fairleigh Dickinson University in New Jersey.

Mr. Wolfgang Mähr

Head of Supervisory Board | Alliance Healthcare Deutschland

Born in Vienna, Wolfgang has joined Herba-Chemosan AG after finishing his studies of pharmacy and having been pharmacy manager for several years. He worked more than 5 years as CEO of the company.

After the acquisition of Herba-Chemosan by Celesio AG, Wolfgang has been nominated CEO of the German pharmaceutical wholesale business GEHE in 2001. From 2006 to 2012 he was member of the Executive Management Board in Celesio AG (today McKesson Europe) responsible for the Pharmacy Solutions division (pharmaceutical wholesale).

In January 2013 he joined Alliance Healthcare, Pharmaceutical Wholesale Division of Alliance Boots as Regional Managing Director.Started his consultancy in March 2015.

Mr. Marco Marsella

Head of the “eHealth, Well-being, and Ageing” Unit | DG CONNECT, European Commission

Marco Marsella is Head of the “eHealth, Well-being, and Ageing” Unit in the Directorate General for Communications Networks, Content and Technology (DG CONNECT) of the European Commission. From 2016 to June 2018, Marco Marsella was leading the Unit responsible for the Web Accessibility Directive, Safer Internet and Language Technologies. He has worked on policy development, innovation and research implementation in the areas of digital content, technologies for learning, e-inclusion and assistive technologies.

Ms. Agnès Mathieu-Mendes

Deputy Head of Unit, Medical products: quality, safety, innovation | European Commission

Agnès Mathieu-Mendes is Deputy Head of the unit dealing with the quality, safety and innovation of medicinal products in the Directorate General on Health and Food Safety in the European Commission. Her responsibilities include the implementation of the Falsified Medicines Directive, the Clinical Trials Regulation, Good Manufacturing Practices, Good Distribution Practices and mutual recognition agreements on GMP with third countries. She has been working for many years in the pharmaceutical field notably with the authorisation process of medicinal products or the orphan medicinal products.

Agnès joined the European Commission in 2006 to work on the Better Regulation agenda of the Directorate General for Enterprise and Industry.

She is a pharmacist by training and has a diploma in pharmaceutical engineering and industrial technology. Prior to the European Commission, Agnès held positions in the pharmaceutical industry and in the Council of Europe.

Ms. Nathalie Moll

Director General | European Federation of Pharmaceutical Industries and Associations (EFPIA)

Nathalie Moll joined the European Federation of Pharmaceutical Industries and Associations (EFPIA) as Director General in April 2017.

EFPIA represents the pharmaceutical industry operating in Europe. Together with its direct membership 40 leading pharmaceutical companies, 33 national associations representing over 1,900 companies and in collaboration with health and research players, EFPIA's mission is to create an environment that enables our members to innovate, discover, develop and deliver new therapies and vaccines for people across Europe, as well as contribute to the European economy.

Prior to joining EFPIA, between 2010 and 2017 Nathalie was the Secretary General of EuropaBio ranked as the most effective European Trade Association in Brussels in 2013. She spent over 20 years working for the biotech industry at EU and national level in associations and corporate positions and held the position of Chair and Vice Chair of the International Council of Biotech Associations (ICBA).

In 2013, Nathalie won the Technovisionaries Women Innovation Award organised by Women & Technologies® while in 2009, Nathalie and the Green Biotech Team of EuropaBio were presented with the Leadership and Excellence in Advancing Ag-Biotech and Food Issues Award. Nathalie was also named one of the 15 leading women in biotech in Europe in 2017.

Nathalie holds an Honours Degree in Biochemistry and Biotechnology from St Andrews University, Scotland.

Mr. Peter O’Donnell

Journalist |

Peter O’Donnell is a Brussels-based journalist who has been covering European affairs for more than twenty years. He has worked for The Financial Times, The Sunday Times, Reuters, the Economist Intelligence Unit, UPI, Euronews, and many other media in Europe and beyond, covering all aspects of EU affairs, and conducting television interviews with leading EU figures on issues of the moment. He is a former editor-in-chief of Europe Information Service, and a former associate editor of European Voice and of POLITICO. He is Brussels correspondent for APM Health Europe and European columnist for Applied Clinical Trials. In addition to his work as a journalist, he acts as editor, editorial adviser and speechwriter for numerous clients in the corporate, political and academic world, and has conceived, created and authored numerous publications for the EU institutions and corporate clients. He frequently acts as moderator or chairman in European-level conferences and debates on a wide range of EU-related subjects, at all levels from informal ministerial meetings to specialised seminars and working groups, on subjects ranging from health to ICT, and from foreign affairs to energy.

Ms. Ilaria Passarani

Secretary General | Pharmaceutical Group of the European Union (PGEU)

Ilaria Passarani is Secretary General of PGEU, the organization representing European Community Pharmacists. She provides strategic direction and leadership to the organization while managing the day to day operations of PGEU and its ongoing relationships with its member associations and other stakeholders, as well as representing the community pharmacy sector in various European and national fora.

Before joining PGEU Ms Passarani worked as Head of the food and health Department at the European Consumer Organization BEUC. She also served as a member of the European Medicines Agency (EMA) Management Board. Ms Passarani graduated in Economics and management from Bocconi University, Italy. Since 2010 she is honorary researcher at the Faculty of Health, Medicine and Life Sciences at the Maastricht University, The Netherlands.

Ms. Paulien Schul

Patient Services & Specialty Services | HEALTH-fi

Paulien started her career as managing pharmacist and has worked in positions developing, implementing and improving pharmaceutical patient care activities. Next to her local (Dutch) pharmaceutical landscape knowledge she expanded her expertise in Europe as Head of Patient Services for PHOENIX.

She has a broad experience in patient care programmes and professional services in order to improve patient outcomes and to improve the visibility of pharmacists as a healthcare provider. As a member of the senior management team she was responsible to cover and guard all pharmaceutical (professional), legal and ethical aspects related to the pharmaceutical business. This is what she still puts first before negotiating with stakeholders the commercial model.

Next to the pharmaceutical expert knowledge of Paulien, she always is looking into improving IT systems, connectivity and interfaces to support and facilitate the operational business of pharmacies and make sure the patient care activities are measured correctly in order to proof the impact delivered by the pharmaceutical patient care interventions. Paulien looks next to the pharmacy channel also into the specialty channel and how to facilitate specialty to keep it accessible.

So what is needed to keep specialty local and close to the trusted environment of the patient, like homecare solutions and nursing services. But also how to make the outcomes of these highly valuable medicines as good as possible, via patient support programmes and adherence services. Finally she developed a value base pricing model for all patient- and specialty services in which the basis is a shared risk-shared benefit model for all stakeholders involved.

Dr. Roger Sorel

Vice President | European Healthcare Distribution Association (GIRP)

Dr. Roger Sorel studied at the University of Utrecht where he graduated in Pharmacy in 1977 and graduated with a Doctor of Science degree in 1982. He has since been working as a pharmacist at a health care insurer, and from 1989 he has held management positions at pharmaceutical wholesalers.
He also followed management training at INSEAD, Fontainebleau, France.

From 1 April 1997 until 1 February 2010 he was Managing Director of Brocacef Holding NV.
From 1 August 2010 Dr. Sorel is member of the Supervisory Board of Brocacef Groep NV that is actual a 55/45 joint venture between Phoenix Pharmahandel GmbH & Co KG and McKesson Europe AG.

For many years he was the Chairman of the Dutch Pharmaceutical Wholesale Association (BG Pharma). He still represents BG-Pharma in GIRP where he is Vice President for the smaller and mid sized countries.

In the pharmaceutical area he is the actual Chairman of the Supervisory Board of Farminform BV and Chairman of the Foundation SIR Institute for Pharmacy Practice and Policy.

Besides the pharmaceutical business he is Chaiman of the Dutch General Wholesale Association (NVG) and Board member of the Dutch Employers Organisation (VNO-NCW).

Mr. Per Troein

Vice President Strategic Partners | IQVIA

Per Troein has been with IQVIA for 19 years and is responsible for the relationship with suppliers and associations. The dispensing and distribution environment is very dynamic. Pricing of pharmaceutical is as complicated. He also has deep insight around generics and biosimilars and how they are handled in different markets. One of IQVIA’ priorities is to have the best understanding of those dynamics to secure the most appropriate data, to be the best partner with the different data partners, and to be able to support the industry and also when appropriate governments. He is a well know speaker in the field of distribution trends and pricing and is very active in consulting projects in the area.

Prior to joining IMS, Per worked 13 years for Pharmacia in US and Europe. His last 6 years were spent in strategic development as a VP including several major mergers and acquisitions.

He holds an MSc in engineering from Lund’s Institute of Technology and an MBA from INSEAD.

You are here